Doctors thought for a long time that immunotherapy wouldn’t work fornon-small-cell lung cancer(NSCLC) and small-cell lung cancer (SCLC), the two most common types. But the past few years have seen several breakthroughs. By the time most people with lung cancer are diagnosed, the disease ...
Immunotherapy for lung cancer: nonspecific immune stimulation Nonspecific immune stimulation has been investigated therapeutically in different cancers, including NSC lung cancer. One agent recently evaluated in NSC lung cancer is talactoferrin alfa, a recombinant form of human lactoferrin and an oral DC-...
Lung cancer is the leading cause of cancer-related death and accounts for approximately 30 % of all cancer deaths. Despite the recent developments in personalized therapy, the prognosis in lung cancer is still very poor. Immunotherapy is now emerging as a new hope for patients with lung cancer....
Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer Lung cancer is the leading cause of cancer deaths worldwide, mainly because it is usually in the advanced stage at the time of diagnosis. Although great progress has been made in the diagnosis and treatment of lu...
The treatment paradigm for lung cancer has been transformed in recent years by the use of immunotherapy, specifically, immune checkpoint antibodies (mAb), which are agents designed to reinvigorate an immune-mediated anticancer response by releasing the effects of tumor-mediated immunosuppression. Late-ph...
A global study, led by UCL and UCLH, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer patients who were not able to be treated with platinum-containing chemotherapy, when compared to single-agent chemotherapy...
L. Cantini, I. Laniado, V. Murthy, D. Sterman, J. G.J.V. Aerts, Immunotherapy for mesothelioma: moving beyond single immune check point inhibition, Lung Cancer (2022), doi: https://doi.org/ 10.1016/j.lungcan.2022.01...
with cutaneous angiosarcoma. They looked at patient tissue samples for the presence of TILs as well as surface proteins PD-1 or PD-L1, which can act as immune checkpoints. Immunotherapy drugs can block PD-1, thereby releasing the brakes on the immune system so that it can attack cancer ...
Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer Clinical Cancer Research An Official Journal of the American Association for Cancer ResearchAnagnostou VK, Brahmer JR. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung ...
Lung cancer: Current status and prospects for the future adenocarcinoma of the lung; Current concepts of chemotherapy and radiotherapy for small cell lung cancer, and Current status of immunotherapy for lung cancer... None - 《Thorax》 被引量: 5发表: 1988年 First-line immunotherapy for advanced...